1st Qtrly 17-18 2nd Qtrly 17-18 3rd Qtrly 17-18 4th Qtrly 17-18 31st ANNUAL REPORT 2016-2017
1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED RESULTS FOR THE QUARTER ENDED : 31ST DECEMBER 2013.

  (Rupees in '000')
S. No. Particulars Un -audited Un-audited Audited
Quarter Ended Nine Month Ended Year
31.Dec.13 30.Sep.13 31.Dec.12 31.Dec.13 31.Dec.12 31.Mar.13
PART-l (a)Income from Operation            
1 Gross Sales 19,323 19,712 16,927 59,747 59,338 76,818
  less Excise Duty 1,036 1,261 1,191 3,695 4,003 5,282
  Net Sales/Income From Operation
18,287
18,451
15,736
56,052
55,335
71,536
  (b) Other Operating Income - - 323 - 323 323
  Total Income from Operation 18,287 18,451 16,059 56,052 55,658 71,859
2 Expenses            
  (a) Cost Of Material Consumed
5,884
5,154
5,178
17,639
18,249
21,402
  (b) Purchase of Stock in Trade 3,503
1,344
942 6,624 4,316 5,460
  (c) Change in Inventories Of Finished Goods and Work in Progress of Stock in trade (1,467) 1,679 (897) 227 (732) 1,702
  (d) Employee Benefit Expenses 6,730 6,614 6,709 19,555 20,182 25,748
  (e) Depreciation & Amortisation Expenses 656 657 653 1,968 1,960 2,619
  (f) Other Expenses 3,047 2,892 2,905 9,336 9,527 12,083
  Total Expenses 18,353 18,340 15,490 55,349 53,502 69,014
3 Profit/(Loss) from Operation Before Other Income ( 1-2) -66 111 569 703 2,156 2,845
4 Other Income 636 299 53 986 508 775
5 Profit /(Loss) from ordinary activities before 570 410 622 1,689 2,664 3,620
6 Finance Cost 270 291 474 966 1,553 2,021
7 Profit /(Loss) from ordinary activities after finance Cost but before Exceptional items ( 5-6) 300 119 148 723 1,111 1,599
8 Exceptional items - - - - - -
9 Profit /(Loss) from ordinary activities before Tax ( 7-8) 300 119 148 723 1,111 1,599
10 Tax Expenses ( Provision for Taxation ) Current tax - - - - - 297
  Deffered tax - - - - - 504
11 Net Profit/(Loss) From Ordinary Activities after Tax (9-10) 300 119 148 723 1,111 798
12 Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears] 354,35 354,35 354,35 354,35 354,35 354,35
13

Reserves Excluding Revaluation Reserves

- - - - - 8,428
14

Earning per share (EPS) before extraordinary item( not Annualised)

- - - - - -
  i) Basic & Diluted - - - - - 0.17
  ii) Diluted - - - - - -
PART-ll

PARTICULARS OF SHAREHOLDING

           
1 Public shareholding            
  i Number of Shares
2,894,901
2,904,901
2,904,901
2,894,901
2,904,901
2,904,901
  ii Percentage of shareholding
63.33%
63.33%
63.55%
63.33%
63.55%
63.55%
2 Promoters and promoter group Shareholding
  a) Pledged/Encumbered
  i Number of shares
  ii Percentage of shares (as a % of the total shareholding of promoter and promoter group)
  iii Percentage of shares (as a% of the total share capital of the company)
  b) Non-encumbered
  - Number of Shares
1,676,099
1,676,099
1,666,099
1,676,099
1,666,099
1,666,099
  - Percentage of shares (as a% of the total shareholding of promoter and promoter group)
36.67%
36.67%
36.45%
36.67%
36.45%
36.45%
  Percentage of shares (as a % of the total share capital of the company)
100%
100%
100%
100%
100%
100%

 

B. INVESTORS COMPLAINTS 3 Months ended 31.12.2013
  Pending at Begining of the Quarter  NIL
  Received During the Quarter NIL
  Disposed of During the Quarter NIL
  Remaining at the end of the Quarter NIL

 

NOTES :-

  1. The above financial results have been taken on record at a meeting of Board of Directors held on 31-01-2014
  2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  3. Previous period figures have been regrouped wherever required.

 

  For and on behalf of the Board
  M/s. COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
31.01.2014 Chairman & Managing Director

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in